MX349354B - Derivado de cicloalcano. - Google Patents

Derivado de cicloalcano.

Info

Publication number
MX349354B
MX349354B MX2014009637A MX2014009637A MX349354B MX 349354 B MX349354 B MX 349354B MX 2014009637 A MX2014009637 A MX 2014009637A MX 2014009637 A MX2014009637 A MX 2014009637A MX 349354 B MX349354 B MX 349354B
Authority
MX
Mexico
Prior art keywords
group
alkyl group
alkoxy
alkyl
halogenated
Prior art date
Application number
MX2014009637A
Other languages
English (en)
Spanish (es)
Other versions
MX2014009637A (es
Inventor
Tsuyoshi Shinozuka
Yuki Domon
Hiroyuki Kobayashi
Sayaka Suzuki
Kyosuke Tanaka
Hiroko Kimoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2014009637A publication Critical patent/MX2014009637A/es
Publication of MX349354B publication Critical patent/MX349354B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014009637A 2012-02-09 2013-02-08 Derivado de cicloalcano. MX349354B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012259122 2012-11-27
PCT/JP2013/052985 WO2013118854A1 (ja) 2012-02-09 2013-02-08 シクロアルカン誘導体

Publications (2)

Publication Number Publication Date
MX2014009637A MX2014009637A (es) 2015-06-23
MX349354B true MX349354B (es) 2017-07-24

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009637A MX349354B (es) 2012-02-09 2013-02-08 Derivado de cicloalcano.

Country Status (30)

Country Link
US (3) US8889741B2 (show.php)
EP (2) EP2813491B1 (show.php)
JP (2) JP5997710B2 (show.php)
KR (1) KR20140127238A (show.php)
CN (1) CN104185629B (show.php)
AU (1) AU2013218592B2 (show.php)
BR (1) BR112014019478A2 (show.php)
CA (1) CA2864222C (show.php)
CO (1) CO7151511A2 (show.php)
CY (1) CY1118572T1 (show.php)
DK (1) DK2813491T3 (show.php)
ES (2) ES2613078T3 (show.php)
HR (1) HRP20161713T1 (show.php)
HU (2) HUE037048T2 (show.php)
IL (1) IL234014A (show.php)
IN (1) IN2014MN01577A (show.php)
LT (1) LT2813491T (show.php)
MX (1) MX349354B (show.php)
NZ (1) NZ628096A (show.php)
PH (2) PH12014501804B1 (show.php)
PL (1) PL2813491T3 (show.php)
PT (1) PT2813491T (show.php)
RS (1) RS55671B1 (show.php)
RU (1) RU2635354C2 (show.php)
SG (1) SG11201404707VA (show.php)
SI (1) SI2813491T1 (show.php)
SM (2) SMT201700053T1 (show.php)
TW (1) TWI612042B (show.php)
WO (1) WO2013118854A1 (show.php)
ZA (1) ZA201405801B (show.php)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853439A1 (en) * 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013177224A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
ES2663798T3 (es) * 2013-03-14 2018-04-17 Daiichi Sankyo Company, Limited Fármaco para enfermedades respiratorias
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
JP6383418B2 (ja) 2013-11-27 2018-08-29 ジェネンテック, インコーポレイテッド 置換ベンズアミド及びその使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CR20170591A (es) 2015-05-22 2018-05-07 Genentech Inc Benzamidas sustituidas y métodos para utilizarlas
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
PE20181003A1 (es) 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
CA3002920A1 (en) 2015-11-06 2017-05-11 Daiichi Sankyo Company, Limited Method for removing dimethoxybenzyl group
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
AU2017268006B2 (en) * 2016-05-20 2021-03-11 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MA46546A (fr) * 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
CN110088093B (zh) * 2016-10-27 2023-06-13 百时美施贵宝公司 酰基磺酰胺NaV1.7抑制剂
RU2760303C2 (ru) 2016-12-09 2021-11-23 Ксенон Фармасьютикалз Инк. Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
WO2019060611A1 (en) 2017-09-20 2019-03-28 Abm Therapeutics, Inc. CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES
WO2019165290A1 (en) * 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
JP7371029B2 (ja) 2018-06-13 2023-10-30 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのその使用
JP7383012B2 (ja) 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
EA202190395A1 (ru) 2018-08-31 2021-06-15 Ксенон Фармасьютикалз Инк. Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
JP2022515630A (ja) * 2018-12-26 2022-02-21 ラクオリア創薬株式会社 Nav1.7およびNav1.8遮断薬としての複素環誘導体
US20240241265A1 (en) * 2023-01-18 2024-07-18 Qualcomm Incorporated Virtual positioning signal measurements

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
CN101218226A (zh) * 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
CA2693588C (en) 2007-07-13 2015-11-17 Icagen, Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
NZ593473A (en) * 2009-01-12 2013-02-22 Pfizer Ltd Sulfonamide derivatives
CA2803118C (en) 2010-07-09 2015-11-03 Pfizer Limited Sulfonamide derivatives as nav 1.7 inhibitors
EP2590951B1 (en) * 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP5872552B2 (ja) * 2010-07-09 2016-03-01 ファイザー・リミテッドPfizer Limited 化学化合物
CA2853439A1 (en) * 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Also Published As

Publication number Publication date
JP6154052B2 (ja) 2017-06-28
EP3144300B1 (en) 2017-12-20
PH12015502675A1 (en) 2017-04-24
US20140045862A1 (en) 2014-02-13
TW201339152A (zh) 2013-10-01
NZ628096A (en) 2016-06-24
EP2813491A1 (en) 2014-12-17
PT2813491T (pt) 2017-02-10
SI2813491T1 (sl) 2017-02-28
RU2635354C2 (ru) 2017-11-13
WO2013118854A1 (ja) 2013-08-15
RU2014136463A (ru) 2016-03-27
US20150018551A1 (en) 2015-01-15
CA2864222A1 (en) 2013-08-15
JPWO2013118854A1 (ja) 2015-05-11
EP3144300A1 (en) 2017-03-22
CA2864222C (en) 2016-10-25
EP2813491A4 (en) 2015-08-12
US9845313B2 (en) 2017-12-19
PH12014501804A1 (en) 2014-11-17
CO7151511A2 (es) 2014-12-29
EP2813491B1 (en) 2016-11-02
PL2813491T3 (pl) 2017-08-31
US8889741B2 (en) 2014-11-18
PH12014501804B1 (en) 2014-11-17
CN104185629A (zh) 2014-12-03
MX2014009637A (es) 2015-06-23
ES2659434T3 (es) 2018-03-15
HRP20161713T1 (hr) 2017-02-10
DK2813491T3 (en) 2017-02-13
AU2013218592B2 (en) 2016-12-22
AU2013218592A1 (en) 2014-09-18
ZA201405801B (en) 2015-12-23
SMT201700053B (it) 2017-03-08
US9493448B2 (en) 2016-11-15
HK1203503A1 (en) 2015-10-30
JP2017008093A (ja) 2017-01-12
LT2813491T (lt) 2017-02-10
JP5997710B2 (ja) 2016-09-28
CY1118572T1 (el) 2017-07-12
US20170001984A1 (en) 2017-01-05
IN2014MN01577A (show.php) 2015-05-08
TWI612042B (zh) 2018-01-21
HUE031450T2 (en) 2017-07-28
IL234014A0 (en) 2014-09-30
CN104185629B (zh) 2017-10-13
KR20140127238A (ko) 2014-11-03
SG11201404707VA (en) 2014-10-30
RS55671B1 (sr) 2017-06-30
ES2613078T3 (es) 2017-05-22
HUE037048T2 (hu) 2018-08-28
SMT201700053T1 (it) 2017-03-08
BR112014019478A2 (pt) 2019-05-28
IL234014A (en) 2017-09-28

Similar Documents

Publication Publication Date Title
PH12014501804A1 (en) Cycloalkane derivative
IN2014DN03063A (show.php)
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
NZ703064A (en) Inhibitors of hepatitis c virus
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
PH12016500553A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
MD20160078A2 (ro) Inhibitori ai Syk
MX2014013957A (es) Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MY177250A (en) Novel nicotinamide derivative or salt thereof
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MX2014006366A (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX2016007440A (es) Inhibidores del bromodominio.
PH12015502429A1 (en) Dicarboxylic acid compound
GEP20207070B (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
MY195177A (en) Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2022006003A (es) Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia.
RU2015155032A (ru) Тилозиновые производные и способ их получения
MX2015015485A (es) Derivado de glicinamida alfa-sustituida.
PH12016501645A1 (en) Aminopyrazolone derivative
MY162537A (en) dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds

Legal Events

Date Code Title Description
FG Grant or registration